<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0505210714
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zonrex
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        824.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Zonrex is zoledronic acid., which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used:</p><p>&bull; <strong>To prevent bone complications, </strong>e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).</p><p>&bull; <strong>To reduce the amount of calcium </strong>in the blood in adult patients where it is too high due to the presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all instructions given to you by your doctor.</p><p>Your doctor will carry out blood tests before you start treatment with Zonrex and will check your response to treatment at regular intervals.</p><p>&nbsp;</p><p><strong>You should not be given Zonrex: </strong></p><p>&minus; If you are breast-feeding.</p><p>&minus; If you are allergic (hypersensitive) to zoledronic acid, another bisphosphonate (the group of</p><p>substances to which zoledronic acid belongs), or any of the other ingredients of Zonrex (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor before being given Zonrex:</p><p>&minus; If you have or have had a <strong>kidney problem. </strong></p><p>&minus; If you have or have had <strong>pain, swelling or numbness </strong>of the jaw, a feeling of heaviness in the jaw or loosening of a tooth. Your doctor may recommend a dental examination before you start treatment with Zonrex</p><p>&ndash; If you are having <strong>dental treatment </strong>or are due to undergo dental surgery, tell your dentist that you are being treated with Zonrex and inform your doctor about your dental treatment.</p><p>While being treated with Zonrex, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.</p><p>Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of a condition called osteonecrosis of the jaw.</p><p>Patients who are undergoing chemotherapy and/or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate (used to treat or prevent bone disorders) may have a higher risk of developing osteonecrosis of the jaw.</p><p>Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with Zonrex. Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia. In some instances the hypocalcaemia may be life-threatening. If any of these apply to you, tell your doctor straight away. If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Zonrex. You will be given adequate calcium and vitamin D supplements.</p><p><strong>&nbsp;</strong></p><p><strong>Patients aged 65 years and over </strong></p><p>Zonrex can be given to people aged 65 years and over. There is no evidence to suggest that any extra precautions are needed.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>Zonrex is not recommended for use in adolescents and children below the age of 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Zonrex</strong></p><p>Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. It is especially important that you tell your doctor if you are also taking:</p><p>&ndash; Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used to treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these</p><p>with bisphosphonates may cause the calcium level in the blood to become too low.</p><p>&ndash; Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys.</p><p>&ndash; Any other medicines that contain zoledronic acid which is used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Zonrex are unknown.</p><p>- Anti-angiogenic medicines (used to treat cancer), since the combination of these with Zonrex has been associated with an increased risk of osteonecrosis of the jaw (ONJ).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>You should not be given Zonrex if you are pregnant. Tell your doctor if you are or think that you may be pregnant.</p><p>You must not be given Zonrex if you are breast-feeding.</p><p>Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines </strong></p><p>There have been very rare cases of drowsiness and sleepiness with the use of Zonrex. You should therefore be careful when driving, using machines or performing other tasks that need full attention.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Zonrex</strong> <strong>contains sodium </strong></p><p>This medicine contains sodium (24 mg) per dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; Zonrex must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein (also referred to as &lsquo;IV&rsquo; administration).</p><p>&minus; Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.</p><p>&ndash; Carefully follow all the other instructions given to you by your doctor, nurse or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>How much Zonrex is given </strong></p><p>&ndash; The usual single dose given is 4 mg.</p><p>&ndash; If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.</p><p><strong>&nbsp;</strong></p><p><strong>How often Zonrex is given </strong></p><p>&ndash; If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Zonrex every three to four weeks.</p><p>&ndash; If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Zonrex.</p><p><strong>&nbsp;</strong></p><p><strong>How Zonrex is given </strong></p><p>&ndash; Zonrex is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.</p><p>Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.</p><p>&nbsp;</p><p><strong>If you are given more Zonrex than you should be </strong></p><p>If you have received doses higher than those recommended, you must be carefully monitored by your doctor. This is because you may develop serum electrolyte abnormalities (e.g. abnormal levels of calcium, phosphorus and magnesium) and/or changes in kidney function, including severe kidney impairment. If your level of calcium falls too low, you may have to be given supplemental calcium by infusion.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Zonrex can cause side effects, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time.</p><p>&nbsp;</p><p><strong>Tell your doctor about any of the following serious side effects straight away: </strong></p><p><strong>Common (may affect up to 1 in 10 people): </strong></p><p>&minus; Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).</p><p>&minus; Low level of calcium in the blood.</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><p>&minus; Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw discharge, numbness or a feeling of heaviness in the jaw or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms while being treated with Zonrex or after stopping treatment.</p><p>&minus; Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.</p><p>&minus; Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people): </strong></p><p>&minus; As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia).</p><p>&minus; A kidney function disorder called Fanconi syndrome (will normally be determined by your doctor with certain urine tests).</p><p>&nbsp;</p><p><strong>Very rare (may affect up to 1 in 10,000 people): </strong></p><p>&minus; As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).</p><p>&minus; Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could be signs of bone damage in the ear.</p><p>&minus; Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh. Tell your doctor immediately if you experience symptoms such as new onset or worsening of aches, pain or stiffness while being treated with Zonrex or after stopping treatment.</p><p>&nbsp;</p><p><strong>Tell your doctor about any of the following side effects as soon as possible: </strong></p><p><strong>Very common (may affect more than 1 in 10 people): </strong></p><p>&minus; Low level of phosphate in the blood.</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people): </strong></p><p>&minus; Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. In most cases no specific treatment is required and the</p><p>symptoms disappear after a short time (couple of hours or days).</p><p>&minus; Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite.</p><p>&minus; Conjunctivitis.</p><p>&minus; Low level of red blood cells (anaemia).</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><p>&minus; Hypersensitivity reactions.</p><p>&minus; Low blood pressure.</p><p>&minus; Chest pain.</p><p>&minus; Skin reactions (redness and swelling) at the infusion site, rash, itching.</p><p>&minus; High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhea, constipation, abdominal pain, dry mouth.</p><p>&minus; Low counts of white blood cells and blood platelets.</p><p>&minus; Low level of magnesium and potassium in the blood. Your doctor will monitor this and take any necessary measures.</p><p>&minus; Weight increase</p><p>&minus; Increased sweating&minus; Sleepiness</p><p>&minus; Blurred vision, tearing of the eye, eye sensitivity to light.</p><p>&minus; Sudden coldness with fainting, limpness or collapse.</p><p>&minus; Difficulty in breathing with wheezing or coughing.</p><p>&minus; Urticaria.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people): </strong></p><p>&minus; Slow heartbeat.</p><p>&minus; Confusion.</p><p>&minus; Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.</p><p>&minus; Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs)</p><p>&minus; Flu-like symptoms including arthritis and joint swelling.</p><p>&minus; Painful redness and/or swelling of the eye.</p><p>&nbsp;</p><p><strong>Very rare (may affect up to 1 in 10,000 people): </strong></p><p>&minus; Fainting due to low blood pressure.</p><p>&minus; Severe bone, joint and/or muscle pain, occasionally incapacitating.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep Zonrex out of the sight and reach of children.</p><p>Do not use Zonrex after the expiry date which is stated on the container after EXP.</p><p>The expiry date refers to the last day of the month.</p><p>Do not store above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; The active substance of Zonrex is zoledronic acid. One vial contains 4 mg zoledronic acid (as monohydrate).</p><p>&minus; The other ingredients are: mannitol, sodium citrate, water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Concentrate for solution for infusion (sterile concentrate)

Clear and colourless solution.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p>&nbsp;MS Pharma-Jordan&nbsp; for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep -2020
SPM190316

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;المادة الفعالة في دواء <strong>زونريكس</strong> هي حمض زوليدرونيك، والذي ينتمي إلى مجموعة دوائية تدعى البسفوسفونات (الفوسفونات الثنائية). يعمل حمض زوليدرونيك عبر ارتباطه مع العظام لإنقاص معدل تغير / تكسر العظم. يستخدم في:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الوقاية من مضاعفات إصابات العظام</strong>؛ على سبيل المثال: الكسور، التي تحدث في المرضى البالغين الذين يعانون من وجود نواقل / ثانويات سرطانية في العظام (انتشار السرطان من موضعه الرئيسي إلى العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إنقاص نسبة الكالسيوم في الدم</strong> في المرضى البالغين عندما تكون نسبته مرتفعة بسبب وجود سرطان. يمكن أن يُسرّع السرطان من عملية التغيير الطبيعية في العظم بصورة ترفع من نسبة الكالسيوم المتحرّر من العظم. تعرف هذه الحالة باسم فرط الكالسيوم في الدم المُستحثّ بواسطة السرطان (TIH).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع كافة الارشادات التي نصحك بها الطبيب أو الصيدلي بعناية.</p><p dir="RTL">&nbsp;سيقوم الطبيب بإجراء فحوصات للدم قبل البدء بتناول هذا الدواء كما أنه سيقوم بمتابعة استجابتك للدواء على فترات زمانية منتظمة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;يجب عدم تناول دواء زونريكس في الحالات الآتية:</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت سيدة تقوم بالرضاعة الطبيعية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من حساسية (فرط تحسس) إلى مادة حمض زوليدرونيك أو أي دواء من فئة البسفوسفونات (الفوسفونات الثنائية) (المجموعة الدوائية التي ينتمي إليها حمض زوليدرونيك)، أو أي مادة من مكونات هذا الدواء (المذكورة في الفقرة 6).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;استشر الطبيب قبل البدء في تناول هذا الدواء:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أو سبق وعانيت من أي <strong>مشكلة في الكلية.</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أو سبق وعانيت من <strong>ألم أو تورم أو خدر</strong> في الفك، وشعور بثقل في الفك أو تراخي في الأسنان. يمكن أن ينصحك الطبيب بإجراء بفحص للأسنان قبل البدء في تناول هذا الدواء.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إخبار طبيب الأسنان عن تناولك هذا الدواء إذا كنت تخضع <strong>لعلاج الأسنان</strong> أو مقرر أن تخضع لعملية جراحية في الأسنان، كما يجب إبلاغ الطبيب المُعالج بهذا الدواء عن علاج أسنانك.</p><p dir="RTL">يجب المحافظة على النظافة الجيدة للفم (بما في ذلك تنظيف الأسنان بصورة منتظمة) وتلقي المتابعة الدورية لحالة الأسنان وذلك أثناء تناولك هذا الدواء. استشر الطبيب المُعالج وطبيب الأسنان على الفور إذا واجهت أي مشاكل في الفم أو الأسنان مثل تراخي الأسنان أو الألم أو التورم أو عدم التئام القروح أو الإفرازات، حيث يمكن أن تكون هذه علامات لحالة تسمى تنخّر عظم الفك.</p><p dir="RTL">المرضى الذين يخضعون للعلاج الكيماوي و/أو العلاج الإشعاعي، أو الذين يتناولون الستيرويد، أو الذين يخضعون لجراحة الأسنان، أو الذين لا يتلقون رعاية الأسنان الدورية، والذين يعانون من أمراض اللثة، والمدخنين، أو الذين سبق علاجهم باستخدام البسفوسفونات (يستخدم لعلاج أو الوقاية من اضطرابات العظام)، قد يكون لديهم خطر أكبر للإصابة بنخر عظم الفك.</p><p dir="RTL">&nbsp;تم الإبلاغ في بعض الحالات التي تعالج بهذا الدواء أن نقص مستويات الكالسيوم في الدم قد يؤدي أحيانا إلى تقلصات في العضلات وجفاف الجلد والشعور بالاحتراق. كما تم الإبلاغ عن بعض الحالات التي عانت من عدم انتظام في ضربات القلب (اختلال نظم القلب)، نوبات صرعية، تشنجات وارتعاش (تقلصات عضلية مستمرة / تكزز) بسبب نقص مستويات الكالسيوم الشديدة. قد يكون نقص الكالسيوم مهددا للحياة في بعض الأحيان. يجب عليك إخبار الطبيب إذا كانت أي من هذه الحالات تنطبق عليك. إذا كنت تعاني من نقص في مستويات الكالسيوم قبل تناول الدواء، فيجب القيام بتصحيح نسبة الكالسيوم إلى المستوى الطبيعي قبل البدء في تناول أول جرعة من الدواء. سيتم إعطاءك كالسيوم وفيتامين د بكمية مناسبة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;المرضى الذين يبلغون من العمر 65 فما أكثر</strong></p><p dir="RTL">&nbsp;يمكن أن يتناول هؤلاء المرضى البالغين من العمر 65 عاما أو أكثر دواء <strong>زونريكس</strong>. لا يوجد دليل يشير إلى أن هناك حاجة لأخذ أي احتياطات إضافية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الأطفال والمراهقين</strong></p><p dir="RTL">&nbsp;لا ينصح بتناول هذا الدواء في الأطفال والمراهقين تحت سن 18 عاما.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع دواء زونريكس</strong></p><p dir="RTL">&nbsp;يجب عليك إخبار الطبيب أو الصيدليّ إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر. يجب عليك إخبار الطبيب إن كنت تتناول أي من هذه الأدوية على وجه التحديد:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمينوجليكوزيد (مضاد حيوي يستخدم لعلاج حالات العدوى الشديدة)، كالسيتونين (نوع من الأدوية يستخدم في علاج هشاشة العظام بعد سن اليأس وفرط الكالسيوم)، مدرات البول الحلقية / العروية (نوع من الأدوية يستخدم في علاج ارتفاع ضغط الدم وتورم الجسم بالماء) أو الأدوية التي تعمل على خفض نسب الكالسيوم، وذلك لأن مزج هذه الأدوية مع البسفوسفونات (الفوسفونات الثنائية) قد ينتج عنه انخفاض شديد في مستويات الكالسيوم في الدم.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثاليدومايد (دواء يستخدم في علاج أنواع معينة من سرطان الدم بما في ذلك سرطان العظام) أو أي أدوية أخرى يمكن أن تتسبب في إحداث ضرر في الكلية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي دواء يحتوي على حمض زوليدرونيك الذي يستخدم في علاج هشاشة العظام وباقي أمراض العظام عدا السرطان، أو أي دواء من فئة البسفوسفونات (الفوسفونات الثنائية)، وذلك لأن التأثيرات الناتجة عن تناول هذه الأدوية مع دواء <strong>زونريكس</strong> غير معلومة.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لتكوين الأوعية الدموية (المستخدمة في علاج السرطان)، يُحذر الجمع بين هذين الدواءين لأن ذلك مرتبط بزيادة مخاطر نخر عظام الفك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">&nbsp;يجب عدم تناول هذا الدواء أثناء الحمل. يجب إبلاغ الطبيب إذا كنت حامل أو تشعرين بأنك حامل.</p><p dir="RTL">&nbsp;يجب عدم تناول هذا الدواء أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;يجب استشارة الطبيب قبل تناول أي دواء في حالات الحمل والرضاعة الطبيعية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;توجد بعض الحالات النادرة للإصابة بالدوار والنعاس عند تناول دواء <strong>زونريكس</strong>. لذلك يجب توخي الحذر أثناء القيادة واستخدام الآلات أو أثناء القيام بمهام تطلب التركيز الكامل.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;يحتوي دواء زونريكس على الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا الدواء على 24 &nbsp;ملغم من الصوديوم في الجرعة الواحدة</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إعطاء هذا الدواء عبر الأفراد المختصة بالرعاية الصحية فقط والمدربين على حقن البسفوسفونات (الفوسفونات الثنائية) عبر الوريد، يعنى ذلك أن هذا الدواء يُتناول عبر الوريد (ويشار إلى ذلك أيضا بـ &quot;IV&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سينصح الطبيب بفائدة شرب كميات كافية من الماء قبل تناول هذا الدواء للمساعدة في الوقاية من الإصابة بالجفاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع كافة الارشادات التي ينصح بها الطبيب أو الممرضة أو الصيدلي بعناية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;مقدار الجرعة المتناولة من دواء زونريكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الاعتيادية الواحدة هي 4 ملغم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في الكلية فإن الطبيب سيقوم بإنقاص الجرعة بالنظر إلى شدة مرض الكلية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;عدد مرات تناول دواء زونريكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج بهذا الدواء من أجل الوقاية من مضاعفات إصابات العظام الناتجة عن النواقل السرطانية للعظم، فإنك ستتناول هذا الدواء لمدة 3 إلى 4 أسابيع عبر التنقيط الوريدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج بهذا الدواء من أجل إنقاص مستويات الكالسيوم في الدم، فإنك ستتناول هذا الدواء لمرة واحدة عبر التنقيط الوريدي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;طريقة استخدام دواء زونريكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيعطى لك هذا الدواء عبر نظام التقطير / التنقيط (عبر المحلول الوريدي) في مدة زمنية لا تقل عن 15دقيقة وينبغي أن تُعطى الجرعة في محلول وريدي واحد وبقسطرة وريدية منفصلة.</p><p dir="RTL">سيتم وصف الكالسيوم وفيتامين د لتناولها كل يوم في حالات المرضى الذين لا يملكون ارتفاعا كبيرا في مستوى الكالسيوم في الدم.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;إذا تناولت جرعة من دواء زونريكس أكبر من الموصى بها</strong></p><p dir="RTL">&nbsp;إذا تلقيت جرعة أكبر من الموصى بها، فيجب على الطبيب متابعتك بعناية فائقة. وذلك لاحتمالية إصابتك باختلال في نسب العناصر المنحلة بالكهرباء (الإلكترولايت) (على سبيل المثال: اختلال في مستويات الكالسيوم، الفسفور، الماغنسيوم) و/أو تغيرات في وظائف الكلية بما في ذلك الإصابة باختلال شديد في الكلية. يجب إعطاؤك مكملات من الكالسيوم عبر المحلول الوريدي إذا تناقصت مستويات الكالسيوم لديم بشدة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى. عادة ما تكون الأعراض الجانبية الأكثر شيوعا خفيفة وربما تختفي بعد فترة قصيرة.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;يجب إبلاغ الطبيب على الفور إذا حدث لك أي من هذه الأعراض الجانبية الخطيرة الآتي ذكرها:</strong></p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية المألوفة (تؤثر في 1 من بين 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال شديد في وظائف الكلى (سيتحدد ذلك بواسطة الطبيب عبر إجراءه بعض الفحوصات المعملية المحددة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص مستويات الكالسيوم في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية غير المألوفة (تؤثر في أقل من 1 إلى 100 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الفم، في الأسنان و/أو الفك، تورم أو قرح غير ملتئمة داخل الفم أو إفرازات من الفك، أو الشعور بخدر أو ثقل في الفك أو تراخي الأسنان. يمكن أن تكون هذه الأعراض علامة لحدوث تلف في عظم الفك (نخر عظمي) يجب إبلاغ الطبيب أو طبيب الأسنان على الفور إذا واجهتك أي من هذه الأعراض أثناء تناولك هذا الدواء أو بعد التوقف عن تناوله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شوهد وجود عدم انتظام في ضربات القلب (رجفان أذيني) في المرضى الذين يتناولون هذا الدواء لعلاج هشاشة العظم التالية لسن اليأس. ليس من الواضح حاليا إن كان هذا الدواء هو المتسبب في عدم انتظام في ضربات القلب، ولكن يجب عليك إبلاغ الطبيب إذا كنت تعاني من هذه الأعراض بعد تلقي هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي شديد: قصر النفس، تورم خاصة في الوجه والحلق.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية النادرة (تؤثر في 1 من بين 1,000 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتيجة لنقص مستويات الكالسيوم في الدم: عدم انتظام في ضربات القلب (اختلال نظم القلب، الناتج عن نقص الكالسيوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال في وظائف الكلية يسمى متلازمة فانكوني (سيتعرف الطبيب على ذلك عند إجراءه بعض فحوصات البول المحددة).</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية النادرة جدا (تؤثر في أقل من 1 من بين 10,000 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتيجة لنقص مستويات الكالسيوم في الدم: نوبات صرعية، تنميل وتقلصات عضلية مستمرة / تكزز (الناتج عن نقص الكالسيوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استشر الطبيب إذا كنت تعاني من ألم في الأذن أو إفرازات من الأذن و/أو عدوى في الأذن. يمكن أن تكون هذه الأعراض علامة لحدوث تلف في الأذن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحدث نخر العظام بصورة نادرة جدا في بعض العظام الأخرى غير الفك، خاصة في عظم الورك والفخذ. يجب إبلاغ الطبيب على الفور إذا واجهتك أعراض مثل: بداية الشعور بوجع أو تفاقم للوجع أو ألم أو تيّبس / تخشب أثناء تناولك هذا الدواء أو بعد التوقف عن تناوله.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;يجب إبلاغ الطبيب في أقرب وقت ممكن إذا حدث لك أي من هذه الأعراض الجانبية الآتي ذكرها:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية المألوفة جدا (تؤثر في أكثر من 1 بين 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص مستويات الفوسفات في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية المألوفة (تؤثر في 1 من بين 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، المتلازمة المشابهة للإنفلونزا المؤلفة من ارتفاع في درجة الحرارة والشعور بالإرهاق والضعف والدوار والقشعريرة وألم في العظم والمفاصل و/أو العضلات. في أغلب الحالات، لا تتطلب هذه الأعراض علاجا معينا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حيث أن هذه الأعراض تختفي بعد فترة قصيرة (عدة ساعات أو أيام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل على مستوى الجهاز الهضمي مثل الغثيان والقيء بالإضافة إلى فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب ملتحمة العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد كرات الدم الحمراء (فقر الدم).</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية غير المألوفة (تؤثر في أقل من 1 بين 100 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل في الجلد (احمرار وتورم) عند موضع الحقن الوريدي، الطفح الجلدي والشعور بالحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، قصر في النفس، الدوار، القلق، اضطراب النوم، اضطراب في حاسة التذوق، ارتجاف / رعشة، شعور بوخز الإبر أو التنميل في اليدين والقدمين، الإسهال، الإمساك، ألم في البطن وجفاف في الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد كرات الدم البيضاء والصفائح الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص مستويات الماغنسيوم والبوتاسيوم في الدم سيقوم الطبيب بمتابعة ذلك وأخذ الإجراءات اللازمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق - زيادة الشعور بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية، زيادة دموع العين، الحساسية للضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ بالبرد أو الإغماء أو العرج أو فقدان الوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس مع صوت أزيز في الصدر أو كحة / سعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتكاريا</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية النادرة (تؤثر في 1 من بين 1,000 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء في سرعة ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الذهن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث كسر غير مألوف في عظم الفخذ خاصة في المرضى الذين يتلقون علاجًا طويل الأجل لمرض هشاشة العظام وذلك في بعض الحالات النادرة. يجب استشارة الطبيب إذا كنت تشعر بألم أو ضعف أو عدم ارتياح في الفخذ أو الورك أو المنطقة الإربية لأن ذلك قد يعد مؤشر مبكر لحدوث كسر في عظم الفخذ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض رئوي خلالي (التهاب في الأنسجة المحيطة بالحويصلات الهوائية في الرئتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مشابهة للإنفلونزا ويشمل ذلك التهاب المفاصل وتورمها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار مؤلم في العين و/أو تورم في العين.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية النادرة جدا (تؤثر في أقل من 1 من بين 10,000 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء بسبب انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في العظم، المفاصل و/أو العضلات، وأحيانا العجز عن الحركة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على شريط الأقراص وعلى العبوة</p><p dir="RTL">&nbsp;بعد كلمة EXP . يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">لا تحفظ الدواء في د رجة حرارة تزيد عن 30 درجة مئوية.</p><p dir="RTL">عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن لا تقم بإلقاء أية أدوية في مياه الصرف أو في النفايات المنزلية،</p><p dir="RTL">&nbsp;وبدلا من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة في دواء <strong>زونريكس</strong> هي حمض زوليدرونيك. تحتوي العبوة (الفيال) على 4 ملغم من حمض زوليدرونيك (على شكل أحادي الهيدرات).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باقي المكونات: مانيتول، سترات الصوديوم والماء من أجل الحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;يتوفر هذا الدواء في صورة سائل مركز (يشار إليه بأنه محلول مركز للتنقيط الوريدي أو تركيز معقّم)</p><p dir="RTL">سائل لا لون له .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:</strong></p><p dir="RTL">إم إس فارما &ndash; الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية\</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر،2020
SPM190316

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zonrex 4mg/5ml concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate).
One ml concentrate contains 0.8 mg zoledronic acid (as monohydrate).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate)
Clear and colourless solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.</p><p>- Treatment of adult patients with tumour-induced hypercalcaemia (TIH).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zonrex must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. Patients treated with Zonrex should be given the package leaflet and the patient reminder card.</p><p><u>Posology</u></p><p><u>Prevention of skeletal related events in patients with advanced malignancies involving bone</u></p><p>Adults and elderly</p><p>The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg Zonrex every 3 to 4 weeks.</p><p>Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.</p><p>The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.</p><p><u>Treatment of TIH</u></p><p>Adults and elderly</p><p>The recommended dose in hypercalcaemia (albumin-corrected serum calcium &ge;12.0 mg/dl or 3.0 mmol/l) is a single dose of 4 mg zoledronic acid.</p><p>Renal impairment</p><p>TIH:</p><p>Zonrex treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine &gt; 400 &micro;mol/l or &gt; 4.5 mg/dl were excluded. No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 &micro;mol/l or &lt; 4.5 mg/dl (see section 4.4).</p><p>Prevention of skeletal related events in patients with advanced malignancies involving bone:</p><p>When initiating treatment with Zonrex in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine using the Cockcroft-Gault formula. Zonrex is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr &lt; 30 ml/min. In clinical trials with zoledronic acid, patients with serum creatinine &gt; 265 &micro;mol/l or &gt; 3.0 mg/dl were excluded.</p><p>In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30&ndash;60 ml/min, the following Zonrex dose is recommended (see also section 4.4):</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Baseline creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Zonrex Recommended Dose*</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 60</p></td><td style="vertical-align:top"><p>4.0 mg zoledronic acid</p></td></tr><tr><td style="vertical-align:top"><p>50&ndash;60</p></td><td style="vertical-align:top"><p>3.5 mg* zoledronic acid</p></td></tr><tr><td style="vertical-align:top"><p>40&ndash;49</p></td><td style="vertical-align:top"><p>3.3 mg* zoledronic acid</p></td></tr><tr><td style="vertical-align:top"><p>30&ndash;39</p></td><td style="vertical-align:top"><p>3.0 mg* zoledronic acid</p></td></tr></tbody></table><p><strong>*</strong>Doses have been calculated assuming target AUC of 0.66 (mg&bull;hr/l) (CLcr=75 ml/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.</p><p>Following initiation of therapy, serum creatinine should be measured prior to each dose of Zonrex and treatment should be withheld if renal function has deteriorated. In the clinical trials, renal deterioration was defined as follows:</p><p>- For patients with normal baseline serum creatinine (&lt; 1.4 mg/dl or &lt; 124 &micro;mol/l), an increase of 0.5 mg/dl or 44 &micro;mol/l;</p><p>- For patients with abnormal baseline creatinine (&gt; 1.4 mg/dl or &gt; 124 &micro;mol/l), an increase of 1.0 mg/dl or 88 &micro;mol/l.</p><p>In the clinical studies, Zonrex treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4). Zonrex treatment should be resumed at the same dose as that given prior to treatment interruption.</p><p>Paediatric population</p><p>The safety and efficacy of Zonrex in children aged 1 year to 17 years have not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p><u>Method of administration</u></p><p>Intravenous use.</p><p>Zonrex, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.</p><p>In patients with mild to moderate renal impairment, reduced Zonrex doses are recommended (see section &ldquo;Posology&rdquo; above and section 4.4).</p><p><u>Instructions for preparing reduced doses of Zonrex</u></p><p>Withdraw an appropriate volume of the concentrate needed, as follows:</p><p>- 4.4 ml for 3.5 mg dose</p><p>- 4.1 ml for 3.3 mg dose</p><p>- 3.8 ml for 3.0 mg dose</p><p>The withdrawn amount of concentrate must be further diluted in 100 ml of sterile sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution. The dose must be given as a single intravenous infusion over no less than 15 minutes.</p><p>Zonrex must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer&#39;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p><p>Patients must be maintained well hydrated prior to and following administration of Zonrex.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed in section 6.1.
• Breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Patients must be assessed prior to administration of Zonrex to ensure that they are adequately hydrated.</p><p>Overhydration should be avoided in patients at risk of cardiac failure.</p><p>Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating Zonrex therapy. If hypocalcaemia, hypophosphataemia, or hypomagnesaemia occurs, short-term supplemental therapy may be necessary. Untreated hypercalcaemia patients</p><p>generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.</p><p>Other products containing zoledronic acid as active substance are available for osteoporosis indications and treatment of Paget&acute;s disease of the bone. Patients being treated with Zonrex should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &quot;sodium-free&quot;.</p><p><u>Renal insufficiency</u></p><p>Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with Zonrex outweighs the possible risk.</p><p>The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2&ndash;3 months.</p><p>Zonrex has been associated with reports of renal dysfunction. Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of Zonrex and other bisphosphonates as well as use of other nephrotoxic medicinal products. While the risk is reduced with a dose of Zonrex administered over 15 minutes, deterioration in renal function may still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid. Increases in serum creatinine also occur in some patients with chronic administration of Zonrex at recommended doses for prevention of skeletal related events, although less frequently.</p><p>Patients should have their serum creatinine levels assessed prior to each dose of zoledronic acid. Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment, lower doses of Zonrex are recommended. In patients who show evidence of renal deterioration during treatment, Zonrex should be withheld. Zonrex should only be resumed when serum creatinine returns to within 10% of baseline. Zonrex treatment should be resumed at the same dose as that given prior to treatment interruption.</p><p>In view of the potential impact of Zonrex on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine &ge;400 &micro;mol/l or &ge;4.5 mg/dl for patients with TIH and &ge;265 &micro;mol/l or &ge;3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance &lt; 30 ml/min), the use of Zonrex is not recommended in patients with severe renal impairment.</p><p><u>Hepatic insufficiency</u></p><p>As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.</p><p><u>Osteonecrosis</u></p><p><u>Osteonecrosis of the jaw</u></p><p>Osteonecrosis of the jaw has been reported uncommonly in clinical trials and in the post-marketing setting in patients receiving zoledronic acid.</p><p>The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth, except in medical emergency situations. A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphosphonates in patients with concomitant risk factors.</p><p>The following risk factors should be considered when evaluating an individual&#39;s risk of developing ONJ:</p><p>- Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate.</p><p>- Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.</p><p>- Concomitant therapies: chemotherapy, angiogenesis inhibitors (see section 4.5), radiotherapy to neck and head, corticosteroids.</p><p>- History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures (e.g. tooth extractions) and poorly fitting dentures</p><p>All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with zoledronic acid.</p><p>While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to Zonrex administration. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. The management plan for patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of Zonrex treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.</p><p>Osteonecrosis of other anatomical sites</p><p>Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.</p><p>Additionally, there have been sporadic reports of osteonecrosis of other sites, including the hip and femur, reported predominantly in adult cancer patients treated with Zonrex.</p><p><u>Musculoskeletal pain</u></p><p>In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients taking Zonrex. However, such reports have been infrequent. The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when rechallenged with Zonrex or another bisphosphonate.</p><p><u>Atypical fractures of the femur</u></p><p>Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.</p><p>During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p><u>Hypocalcaemia</u></p><p>Hypocalcaemia has been reported in patients treated with zoledronic acid. Cardiac arrhythmias and neurologic adverse events (including convulsions, hypoaesthesia and tetany) have been reported secondary to cases of severe hypocalcaemia. Cases of severe hypocalcaemia requiring hospitalisation have been reported. In some instances, the hypocalcaemia may be life-threatening (see section 4.8). Caution is advised when Zonrex is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5). Serum calcium should be measured and hypocalcaemia must be corrected before initiating Zonrex therapy. Patients should be adequately supplemented with calcium and vitamin D.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, Zonrex has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring. Zonrex shows no appreciable binding to plasma proteins and does not inhibit human P450 enzymes&nbsp;in vitro&nbsp;(see section 5.2), but no formal clinical interaction studies have been performed.</p><p>&nbsp;</p><p>Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4).</p><p>Caution is indicated when Zonrex is used with other potentially nephrotoxic medicinal products. Attention should also be paid to the possibility of hypomagnesaemia developing during treatment.</p><p>In multiple myeloma patients, the risk of renal dysfunction may be increased when Zonrex is used in combination with thalidomide.</p><p>Caution is advised when Zonrex is administered with anti-angiogenic medicinal products as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on the use of Zonrex in pregnant women. Animal reproduction studies with Zonrex have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Zonrex should not be used during pregnancy. Women of child-bearing potential should be advised to avoid becoming pregnant.</p><p><u>Breast-feeding</u></p><p>It is not known whether Zonrex is excreted into human milk. Zonrex is contraindicated in breast-feeding women (see section 4.3).</p><p><u>Fertility</u></p><p>Zonrex was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. This resulted in exaggerated pharmacological effects considered to be related to the compound&#39;s inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. Thus these results precluded determining a definitive effect of Zonrex on fertility in humans.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Zonrex along with driving and operating of machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Within three days after Zonrex administration, an acute phase reaction has commonly been reported, with symptoms including bone pain, fever, fatigue, arthralgia, myalgia, rigors and arthritis with subsequent joint swelling; these symptoms usually resolve within a few days (see description of selected adverse reactions).</p><p>The following are the important identified risks with Zonrex in the approved indications:</p><p>Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease. The frequencies for each of these identified risks are shown in Table 1.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:</p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><strong>Table 1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombocytopenia, leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypersensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Angioneurotic oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Anxiety, sleep disturbance</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Confusion</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, paraesthesia, dysgusia, hypoaesthesia, hyperaesthesia, tremor, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Convulsions, hypoaesthesia and tetany (secondary to hypocalcaemia)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Blurred vision, scleritis and orbital inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Uveitis</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Episcleritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dyspnoea, cough, bronchoconstriction</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Interstitial lung disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nausea, vomiting, decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pruritus, rash (including erythematous and macular rash), increased sweating</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Bone pain, myalgia, arthralgia, generalised pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Muscle spasms, osteonecrosis of the jaw</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)&nbsp;<u>and other anatomical sites including femur and hip</u></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Renal impairment</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Acute renal failure, haematuria, proteinuria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Acquired Fanconi syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Arthritis and joint swelling as a symptom of acute phase reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hypophosphataemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Blood creatinine and blood urea increased, hypocalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypomagnesaemia, hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hyperkalaemia, hypernatraemia</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p>Renal function impairment</p><p>Zonrex has been associated with reports of renal dysfunction. In a pooled analysis of safety data from trials for the use of Zonrex for the prevention of skeletal-related events in patients with advanced malignancies involving bone, the frequency of renal impairment adverse events suspected to be related to Zonrex (adverse reactions) was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%). Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of Zonrex or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg Zonrex (see section 4.4).</p><p>Osteonecrosis of the jaw</p><p>Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as Zonrex (see section 4.4). Many of these patients were also receiving chemotherapy and corticosteroids and had signs of local infection including osteomyelitis. The majority of the reports refer to cancer patients following tooth extractions or other dental surgeries.</p><p>Atrial fibrillation</p><p>In one 3-year, randomized, double-blind controlled trial that evaluated the efficacy and safety of Zonrex 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving Zonrex 5 mg and placebo, respectively. The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving Zonrex 5 mg and placebo, respectively. The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with Zonrex 4 mg every 3-4 weeks in oncology patients. The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.</p><p>Acute phase reaction</p><p>This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhoea, arthralgia and arthritis with subsequent joint swelling. The onset time is &le;3 days post-Zonrex infusion, and the reaction is also referred to using the terms &ldquo;flu-like&rdquo; or &ldquo;post-dose&rdquo; symptoms.</p><p>Atypical fractures of the femur</p><p>During post-marketing experience the following reactions have been reported (frequency rare):</p><p>Atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction).</p><p>Hypocalcaemia-related ADRs</p><p>Hypocalcaemia is an important identified risk with Zonrex in the approved indications. Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between Zonrex therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia. Furthermore, there is evidence of an association between hypocalcaemia and secondary neurological events reported in these cases including; convulsions, hypoaesthesia and tetany (see section 4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.65pt;margin-top:6.25pt;width:375.05pt;height:100pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>-
    The National Pharmacovigilance and Drug Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Fax:
    +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Toll free
    phone: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: www.sfda.gov.sa</span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoNormal style='text-indent:-18.0pt'><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="139" alt="Text Box: - The National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Toll free phone: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa

" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9 Overdose</strong></p><p>Clinical experience with acute overdose of Zonrex is limited. The administration of doses up to 48 mg of Zonrex in error has been reported. Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. In the event of hypocalcaemia, calcium gluconate infusions should be administered as clinically indicated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Medicinal products for treatment of bone diseases, bisphosphonates, ATC code: M05BA08</p><p>Zonrex belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption.</p><p>The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. In long-term animal studies, Zonrex inhibits bone resorption without adversely affecting the formation, mineralisation or mechanical properties of bone.</p><p>In addition to being a potent inhibitor of bone resorption, Zonrex also possesses several anti-tumour properties that could contribute to its overall efficacy in the treatment of metastatic bone disease. The following properties have been demonstrated in preclinical studies:</p><p>-&nbsp;In vivo:&nbsp;Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity.</p><p>-&nbsp;In vitro:&nbsp;Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer medicinal products, anti-adhesion/invasion activity.</p><p><u>Clinical trial results in the prevention of skeletal related events in patients with advanced malignancies involving bone</u></p><p>The first randomised, double-blind, placebo-controlled study compared Zonrex 4 mg to placebo for the prevention of skeletal related events (SREs) in prostate cancer patients. Zonrex 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate. Multiple event analysis showed a 36% risk reduction in developing SREs in the Zonrex 4 mg group compared with placebo. Patients receiving Zonrex 4 mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24. Fewer Zonrex 4 mg patients suffered pathological fractures. The treatment effects were less pronounced in patients with blastic lesions. Efficacy results are provided in Table 2.</p><p>In a second study including solid tumours other than breast or prostate cancer, Zonrex 4 mg significantly reduced the proportion of patients with an SRE, delayed the median time to first SRE by &gt; 2 months, and reduced the skeletal morbidity rate. Multiple event analysis showed 30.7% risk reduction in developing SREs in the Zonrex 4 mg group compared with placebo. Efficacy results are provided in Table 3.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 2:</strong>&nbsp;Efficacy results (prostate cancer patients receiving hormonal therapy)</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><u>Any SRE (+TIH)</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Fractures*</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Radiation therapy to bone</u></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>214</p></td><td style="vertical-align:top"><p>208</p></td><td style="vertical-align:top"><p>214</p></td><td style="vertical-align:top"><p>208</p></td><td style="vertical-align:top"><p>214</p></td><td style="vertical-align:top"><p>208</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients with SREs (%)</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.028</p></td><td colspan="2" style="vertical-align:top"><p>0.052</p></td><td colspan="2" style="vertical-align:top"><p>0.119</p></td></tr><tr><td style="vertical-align:top"><p>Median time to SRE (days)</p></td><td style="vertical-align:top"><p>488</p></td><td style="vertical-align:top"><p>321</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>640</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.009</p></td><td colspan="2" style="vertical-align:top"><p>0.020</p></td><td colspan="2" style="vertical-align:top"><p>0.055</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal morbidity rate</p></td><td style="vertical-align:top"><p>0.77</p></td><td style="vertical-align:top"><p>1.47</p></td><td style="vertical-align:top"><p>0.20</p></td><td style="vertical-align:top"><p>0.45</p></td><td style="vertical-align:top"><p>0.42</p></td><td style="vertical-align:top"><p>0.89</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.005</p></td><td colspan="2" style="vertical-align:top"><p>0.023</p></td><td colspan="2" style="vertical-align:top"><p>0.060</p></td></tr><tr><td style="vertical-align:top"><p>Risk reduction of suffering from multiple events** (%)</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.002</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td></tr></tbody></table><p>* Includes vertebral and non-vertebral fractures</p><p>** Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p>NR Not Reached</p><p>NA Not Applicable</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 3:</strong>&nbsp;Efficacy results (solid tumours other than breast or prostate cancer)</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><u>Any SRE (+TIH)</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Fractures*</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Radiation therapy to bone</u></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>257</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>257</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>257</p></td><td style="vertical-align:top"><p>250</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients with SREs (%)</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>34</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.039</p></td><td colspan="2" style="vertical-align:top"><p>0.064</p></td><td colspan="2" style="vertical-align:top"><p>0.173</p></td></tr><tr><td style="vertical-align:top"><p>Median time to SRE (days)</p></td><td style="vertical-align:top"><p>236</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>424</p></td><td style="vertical-align:top"><p>307</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.009</p></td><td colspan="2" style="vertical-align:top"><p>0.020</p></td><td colspan="2" style="vertical-align:top"><p>0.079</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal morbidity rate</p></td><td style="vertical-align:top"><p>1.74</p></td><td style="vertical-align:top"><p>2.71</p></td><td style="vertical-align:top"><p>0.39</p></td><td style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>1.24</p></td><td style="vertical-align:top"><p>1.89</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.012</p></td><td colspan="2" style="vertical-align:top"><p>0.066</p></td><td colspan="2" style="vertical-align:top"><p>0.099</p></td></tr><tr><td style="vertical-align:top"><p>Risk reduction of suffering from multiple events** (%)</p></td><td style="vertical-align:top"><p>30.7</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.003</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td></tr></tbody></table><p>* Includes vertebral and non-vertebral fractures</p><p>** Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p>NR Not Reached</p><p>NA Not Applicable</p><p>In a third phase III randomised, double-blind trial, Zonrex 4 mg or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. The results demonstrated that Zonrex 4 mg showed comparable efficacy to 90 mg pamidronate in the prevention of SREs. The multiple event analysis revealed a significant risk reduction of 16% in patients treated with Zonrex 4 mg in comparison with patients receiving pamidronate. Efficacy results are provided in Table 4.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 4:&nbsp;</strong>Efficacy results (breast cancer and multiple myeloma patients)</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><u>Any SRE (+TIH)</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Fractures*</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Radiation therapy to bone</u></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Pam 90 mg</p></td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Pam 90 mg</p></td><td style="vertical-align:top"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top"><p>Pam 90 mg</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>561</p></td><td style="vertical-align:top"><p>555</p></td><td style="vertical-align:top"><p>561</p></td><td style="vertical-align:top"><p>555</p></td><td style="vertical-align:top"><p>561</p></td><td style="vertical-align:top"><p>555</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients with SREs (%)</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.198</p></td><td colspan="2" style="vertical-align:top"><p>0.653</p></td><td colspan="2" style="vertical-align:top"><p>0.037</p></td></tr><tr><td style="vertical-align:top"><p>Median time to SRE (days)</p></td><td style="vertical-align:top"><p>376</p></td><td style="vertical-align:top"><p>356</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>714</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.151</p></td><td colspan="2" style="vertical-align:top"><p>0.672</p></td><td colspan="2" style="vertical-align:top"><p>0.026</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal morbidity rate</p></td><td style="vertical-align:top"><p>1.04</p></td><td style="vertical-align:top"><p>1.39</p></td><td style="vertical-align:top"><p>0.53</p></td><td style="vertical-align:top"><p>0.60</p></td><td style="vertical-align:top"><p>0.47</p></td><td style="vertical-align:top"><p>0.71</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.084</p></td><td colspan="2" style="vertical-align:top"><p>0.614</p></td><td colspan="2" style="vertical-align:top"><p>0.015</p></td></tr><tr><td style="vertical-align:top"><p>Risk reduction of suffering from multiple events** (%)</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.030</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td></tr></tbody></table><p>* Includes vertebral and non-vertebral fractures</p><p>** Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p>NR Not Reached</p><p>NA Not Applicable</p><p>Zonrex 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg Zonrex on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period. Patients received either 4 mg Zonrex or placebo every four weeks for one year. Patients were evenly distributed between Zonrex -treated and placebo groups.</p><p>The SRE rate (events/person year) was 0.628 for Zonrex and 1.096 for placebo. The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the Zonrex -treated group versus 49.6% in the placebo group (p=0.003). Median time to onset of the first SRE was not reached in the Zonrex -treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). Zonrex 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.</p><p>In the Zonrex -treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1). The pain score for Zonrex was consistently below baseline and pain reduction was accompanied by a trend in reduced analgesics score.</p><p><strong>Figure 1: Mean changes from baseline in BPI scores. Statistically significant differences are marked (*p&lt;0.05) for between treatment comparisons (4 mg Zonrex vs. placebo)</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="https://www.medicines.org.uk/emc/images/spc/spc~27770~12~150469.PNG"
 style='width:420pt;height:4in;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="spc~27770~12~150469"/>
</v:shape><![endif]--><img width="560" height="384" alt="https://www.medicines.org.uk/emc/images/spc/spc~27770~12~150469.PNG" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></p><p><u>Clinical trial results in the treatment of TIH</u></p><p>Clinical studies in tumour-induced hypercalcaemia (TIH) demonstrated that the effect of Zonrex is characterised by decreases in serum calcium and urinary calcium excretion. In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2&ndash;2.5 mg.</p><p>To assess the effects of 4 mg Zonrex versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis. There was faster normalisation of corrected serum calcium at day 4 for 8 mg Zonrex and at day 7 for 4 mg and 8 mg zoledronic acid. The following response rates were observed:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 5:</strong>&nbsp;Proportion of complete responders by day in the combined TIH studies</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Day 4</p></td><td style="vertical-align:top"><p>Day 7</p></td><td style="vertical-align:top"><p>Day 10</p></td></tr><tr><td style="vertical-align:top"><p>Zonrex 4 mg (N=86)</p></td><td style="vertical-align:top"><p>45.3% (p=0.104)</p></td><td style="vertical-align:top"><p>82.6% (p=0.005)*</p></td><td style="vertical-align:top"><p>88.4% (p=0.002)*</p></td></tr><tr><td style="vertical-align:top"><p>Zonrex 8 mg (N=90)</p></td><td style="vertical-align:top"><p>55.6% (p=0.021)*</p></td><td style="vertical-align:top"><p>83.3% (p=0.010)*</p></td><td style="vertical-align:top"><p>86.7% (p=0.015)*</p></td></tr><tr><td style="vertical-align:top"><p>Pamidronate 90 mg (N=99)</p></td><td style="vertical-align:top"><p>33.3%</p></td><td style="vertical-align:top"><p>63.6%</p></td><td style="vertical-align:top"><p>69.7%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*p-values compared to pamidronate.</p></td></tr></tbody></table><p>Median time to normocalcaemia was 4 days. Median time to relapse (re-increase of albumin-corrected serum calcium &ge;2.9 mmol/l) was 30 to 40 days for patients treated with Zonrex versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid). There were no statistically significant differences between the two Zonrex doses.</p><p>In clinical trials 69 patients who relapsed or were refractory to initial treatment (Zonrex 4 mg, 8 mg or pamidronate 90 mg) were retreated with 8 mg zoledronic acid. The response rate in these patients was about 52%. Since those patients were retreated with the 8 mg dose only, there are no data available allowing comparison with the 4 mg Zonrex dose.</p><p>In clinical trials performed in patients with tumour-induced hypercalcaemia (TIH), the overall safety profile amongst all three treatment groups (Zonrex 4 and 8 mg and pamidronate 90 mg) was similar in types and severity.</p><p><u>Paediatric population</u></p><p><u>Clinical trial results in the treatment of severe osteogenesis imperfecta in paediatric patients aged 1 to 17 years</u></p><p>The effects of intravenous Zonrex in the treatment of paediatric patients (age 1 to 17 years) with severe osteogenesis imperfecta (types I, III and IV) were compared to intravenous pamidronate in one international, multicentre, randomised, open-label study with 74 and 76 patients in each treatment group, respectively. The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks. In the clinical programme patients aged 1 to &lt; 3 years received 0.025 mg/kg Zonrex (up to a maximum single dose of 0.35 mg) every 3 months and patients aged 3 to 17 years received 0.05 mg/kg Zonrex (up to a maximum single dose of 0.83 mg) every 3 months. An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly Zonrex over the 12-month extension treatment period in children who had completed one year of treatment with either Zonrex or pamidronate in the core study.</p><p>The primary endpoint of the study was the percent change from baseline in lumbar spine bone mineral density (BMD) after 12 months of treatment. Estimated treatment effects on BMD were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid. In particular there was no clear evidence of efficacy on incidence of fracture or on pain. Fracture adverse events of long bones in the lower extremities were reported in approximately 24% (femur) and 14% (tibia) of zoledronic acid-treated patients vs 12% and 5% of pamidronate-treated patients with severe osteogenesis imperfecta, regardless of disease type and causality but overall incidence of fractures was comparable for the Zonrex and pamidronate-treated patients: 43% (32/74) vs 41% (31/76). Interpretation of the risk of fracture is confounded by the fact that fractures are common events in patients with severe osteogenesis imperfecta as part of the disease process.</p><p>The type of adverse reactions observed in this population were similar to those previously seen in adults with advanced malignancies involving the bone (see section 4.8). The adverse reactions ranked under headings of frequency, are presented in Table 6. The following conventional classification is used: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 6:</strong>&nbsp;Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Vomiting, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pain in extremities, arthralgia, musculoskeletal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Pyrexia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Acute phase reaction, pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hypocalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypophosphataemia</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of Zonrex (see section 4.8)</p><p>In paediatric patients with severe osteogenesis imperfecta, Zonrex seems to be associated with more pronounced risks for acute phase reaction, hypocalcaemia and unexplained tachycardia, in comparison to pamidronate, but this difference declined after subsequent infusions.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing Zonrex in all subsets of the paediatric population in the treatment of tumour-induced hypercalcaemia and prevention of skeletal-related events in patients with advanced malignancies involving bone (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg Zonrex in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.</p><p>After initiating the infusion of zoledronic acid, the plasma concentrations of Zonrex rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of Zonrex on day 28.</p><p>Intravenously administered Zonrex is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t<sub>&frac12;&alpha;</sub>&nbsp;0.24 and t<sub>&frac12;&beta;</sub>&nbsp;1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t<sub>&frac12;&gamma;</sub>&nbsp;146 hours. There was no accumulation of Zonrex in plasma after multiple doses given every 28 days. Zonrex is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, 39 &plusmn; 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is 5.04 &plusmn; 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in Zonrex concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.</p><p>The interpatient variability in pharmacokinetic parameters for Zonrex was high, as seen with other bisphosphonates.</p><p>No pharmacokinetic data for Zonrex are available in patients with hypercalcaemia or in patients with hepatic insufficiency. Zonrex does not inhibit human P450 enzymes&nbsp;in vitro, shows no biotransformation and in animal studies &lt; 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.</p><p>The renal clearance of Zonrex was correlated with creatinine clearance, renal clearance representing 75 &plusmn; 33% of the creatinine clearance, which showed a mean of 84 &plusmn; 29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied. Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of Zonrex would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 ml/min. Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance &lt; 30 ml/min).</p><p>In an in vitro study, Zonrex showed low affinity for the cellular components of human blood, with a mean blood to plasma concentration ratio of 0.59 in a concentration range of 30 ng/ml to 5000 ng/ml. The plasma protein binding is low, with the unbound fraction ranging from 60% at 2 ng/ml to 77% at 2000 ng/ml of zoledronic acid.</p><p><u>Special populations</u></p><p><u>Paediatric patients</u></p><p>Limited pharmacokinetic data in children with severe osteogenesis imperfecta suggest that Zonrex pharmacokinetics in children aged 3 to 17 years are similar to those in adults at a similar mg/kg dose level. Age, body weight, gender and creatinine clearance appear to have no effect on Zonrex systemic exposure.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acute toxicity</u></p><p>The highest non-lethal single intravenous dose was 10 mg/kg bodyweight in mice and 0.6 mg/kg in rats.</p><p><u>Subchronic and chronic toxicity</u></p><p>Zonrex was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses up to 0.02 mg/kg daily for 4 weeks. Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2&ndash;3 days in dogs for up to 52 weeks was also well tolerated.</p><p>The most frequent finding in repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound&#39;s pharmacological antiresorptive activity.</p><p>The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06&ndash;0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose. Longer-term repeat administration at doses bracketing the highest intended human therapeutic dose of Zonrex produced toxicological effects in other organs, including the gastrointestinal tract, liver, spleen and lungs, and at intravenous injection sites.</p><p><u>Reproduction toxicity</u></p><p>Zonrex was teratogenic in the rat at subcutaneous doses &ge;0.2 mg/kg. Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found. Dystocia was observed at the lowest dose (0.01 mg/kg bodyweight) tested in the rat.</p><p><u>Mutagenicity and carcinogenic potential</u></p><p>Zonrex was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Sodium citrate</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To avoid potential incompatibilities, Zonrex is to be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution.</p><p>This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer&#39;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
After dilution: From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C – 8°C. The refrigerated solution should then be equilibrated to room temperature prior to administration.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep Zonrex out of the sight and reach of children.</p><p>Do not use Zonrex after the expiry date which is stated on the container after EXP.</p><p>The expiry date refers to the last day of the month.</p><p>Do not store above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Flip off seal 20mm Specification</p><p>Pack size</p><p>Zonrex is supplied as packs containing 1 vial (5ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prior to administration, 5.0 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 ml of calcium-free infusion solution (sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution).</p><p>Additional information on handling of Zonrex, including guidance on preparation of reduced doses, is provided in section 4.2.</p><p>Aseptic techniques must be followed during the preparation of the infusion. For single use only.</p><p>Only clear solution free from particles and discolouration should be used.</p><p>Healthcare professionals are advised not to dispose of unused Zonrex via the domestic sewage system.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>